久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • AZ' Calquence shows PFS benefit in CLL patients pharmatimes
    June 18, 2019
    AstraZeneca has presented detailed data showing that Calquence (acalabrutinib) significantly prolonged progression free survival (PFS) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service